Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Tanios S. Bekaii-Saab presents a case of advanced HCC that elucidates the role of immunotherapy. © 2019 Imedex, an HMP Company
Author: Editor
Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Ghassan Abou-Alfa discusses novel agents and therapeutic targets for the treatment of biliary cancer. © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/19-gdugi-5 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Pashtoon Kasi discusses best practices for the management of adverse events associated with the treatment of HCC. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Michael A. Choti argues in favor of utilizing adjuvant FOLFIRINOX for the treatment of pancreatic cancer. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-gdu… In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Jordan D. Berlin argues in favor of utilizing preoperative chemo/chemoradiotherapy for the treatment of pancreatic cancer. © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Christopher L. Hallemeier argues in favor of utilizing stereotactic body radiation therapy (SBRT) for the preoperative treatment of borderline resectable pancreatic cancer. © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Christopher Crane argues in favor of utilizing conventional radiation therapy for the preoperative treatment of borderline resectable pancreatic cancer. © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Tanios S. Bekaii-Saab presents a case of hepatocellular carcinoma (HCC) that elucidates the role of imunotherapy. © 2019 Imedex, an HMP Company
Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Pashtoon Kasi discusses the best practices for the management of adverse events associated with therapies utilized in the treatment of hepatocellular carcinoma (HCC). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse Events Management’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, the session panel discuss cases elucidating the finer points of individualized treatment selection and therapeutic sequencing in next-line metastatic colorectal cancer. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-cpc-101-7 This webcast features a presentation by Dr. Gary H. Lyman that examines the potential benefits of incorporating biosimilars into oncology clinical pathways. © 2019 NACCME, an HMP Company
Earn CME: https://www.naccme.com/program/19-cpc-101-6 This webcast features a presentation by Dr. Alexander B. Olawaiye that discusses the integration of PARP inhibitors into evidence-based ovarian cancer clinical pathways based on discrete PARP factors, latest clinical data, and guideline recommendations for the treatment of ovarian cancer. © 2019 NACCME, an HMP Company
Earn CME: https://www.naccme.com/program/19-cpc-101-5 This webcast features a presentation by Dr. Atish D. Choudhury that examines the latest clinical safety and efficacy data surrounding next-generation antiandrogen agents for initial treatment of localized hormone-sensitive prostate cancer (HSPC). © 2019 NACCME, an HMP Company
Earn CME: https://www.naccme.com/program/19-cpc-101-4 This webcast features a presentation by Dr. Amir T. Fathi on best practices for the integration of recent therapeutic advances, resource utilization data, and current guidance into AML clinical pathways discussions. © 2019 NACCME, an HMP Company
Earn CME: https://www.naccme.com/program/19-cpc-101-3 This webcast features a presentation by Dr. David Jackman discusses the latest efficacy and safety data, indications, and cost utility of novel therapies into optimal selection and non-small cell lung cancer (NSCLC) pathway placement strategies. © 2019 NACCME, an HMP Company
Earn CME: https://www.naccme.com/program/19-cpc-101-2 This webcast features a presentation by Dr. Gabriella Hobbs that examines the most recent evidence-based guidelines to optimize individualized tyrosine kinase inhibitor (TKI) selection for chronic myeloid leukemia (CML) patients based on disease phase, treatment history, genetic mutation profile, and comorbidities, © 2019 NACCME, an HMP Company
Earn CME: https://www.naccme.com/program/19-cpc-101-1 This webcast features a presentation by Dr. Nicole M. Kuderer that examines pharmacological profiles of novel and emerging metastatic breast cancer (MBC) agents, including their indications, potential place in therapy, and recent clinical data. © 2019 NACCME, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-15 In this webcast from the ‘New and Emerging Agents in MCL’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Michael E. Williams discusses novel agents for the treatment of mantle cell lymphoma (MCL). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-14 In this webcast from the ‘Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic & Targeted Approaches’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. John P. Leonard discusses the current state of upfront management of diffuse large b-cell lymphoma (DLBCL). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Thomas M. Habermann discusses the treatment of marginal zone lymphoma (MZL). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Thomas M. Habermann discusses whether treatment of marginal zone lymphoma (MZL) should be different than that of follicular lymphoma. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Martin, Casulo, Fischer, Cheson, and Haberman discuss the treatment of lymphoma on a panel discussion. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Bruce D. Cheson and Richard I. Fisher debate whether chemotherapy still has a major role in the treatment of follicular lymphoma. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K Inhibitors’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Peter Martin and Carla Casulo debate whether patients with follicular lymphoma should be treated immediately. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Barrientos and Park discuss their presentations and answer questions on the treatment of hairy cell leukemia (HCL). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Jae Park discusses new and emerging treatment options for patients with hairy cell leukemia (HCL). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Jacqueline C. Barrientos discusses the efficacy and safety of current treatment options for hairy cell leukemia (HCL). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Steven B. Treon discusses treatment options for a a series of cases of Waldenström’s Macroglobulinemia. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Steven B. Treon discusses his approach to the treatment of Waldenström’s Macroglobulinemia. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. James R. Berenson, Adam D. Cohen, Deepu Madduri, and Sham Mailankody discuss the current and future state of CAR-T therapy for myeloma patients. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Adam D. Cohen discusses next-generation CAR-T produces and strategies. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Sham Mailankody discusses responses to CAR-T therapy in patients with myeloma. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-06 In this webcast from the ‘New Immunological Approaches to Myeloma: CAR T-Cell Therapy and Other Novel Strategies’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. James R. Berenson discusses the role of b-cell maturation antigen (BCMA) in predicting outcomes and monitoring patients with multiple myeloma or chronic lymphocytic leukemia. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Raphael Fonseca discusses use the of MRD testing, single cell RNA sequencing, and cell free DNA testing in the treatment of hematologic malignancies. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses the use of MRD as a target for the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Desai, Lee, Roboz, and van Besien discuss their presentations and answer questions. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Pinkal Desai and Sangmin Lee debate whether patients in major molecular remission © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-02 In this webcast from the ‘Advances in TKI Therapy for CML: Navigating the Future Treatment Landscape’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Sangmin Lee discusses current approaches to optimizing care. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Desai, Lee, and Roboz elaborate on their presentations from the symposium. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Pinkal Desai and Sangmin Lee debate whether venetoclax + azacitidine/decitabine/LDAC should be the new standard of care for acute myeloid leukemia (AML) patients greater than equal to 60 years of age. © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses novel targeted therapies for the treatment of newly diagnosed acute myeloid leukemia (AML). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses novel therapies for the treatment of newly diagnosed acute myeloid leukemia (AML). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-04 In this webcast from the ‘Recent Advances in Acute Leukemia Management’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Pinkal Desai discusses therapeutic strategies for the difficult-to-treat patient with acute lymphocytic leukemia (ALL). © 2019 Imedex, an HMP Company
Earn CME: https://www.naccme.com/program/19-lm-05 In this webcast from the ‘Multiple Myeloma: Treatment Challenges and Updates’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Deepu Madduri discusses best practices for dealing with adverse events and toxicities related to CAR-T therapy.
Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the alkylating properties in the treatment of relapsed/refractory multple myeloma. ________________ Oncopeptides highlighted its topline results for the pivotal HORIZON study: melflufen (INN melphalan flufenamide) showing a 26% overall response rate in triple-class RRMM patients, a patient population who currently have limited treatment options.  Of note, these results will form the basis for the accelerated NDA in the US, with the application on track for a submission to the FDA at the end of Q2 2020. For further background on this news, Oncopeptides hosted a webcast today to provide an update on the final study…
Zachary Frosch, MD of Penn Medicine @PennMedicine explains that more prospective data is needed to validate stratification of molecular risk in aggressive b-cell lymphoma. Diffuse large B-cell lymphoma (DLBCL) has become increasingly evident in recent years as not a single pathological entity. Wide-ranging diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to sub-categorize DLBCLs by their pathological characteristics and classify those associated with lower likelihood of cure with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) rituximab after typical first-line cure. This recognition has prompted expanded use of diagnostic testing to classify patients with high-risk severe…
Zachary Frosch, MD of Penn Medicine @PennMedicine answers how stratification of molecular risk in aggressive b-cell lymphoma is validated. Diffuse large B-cell lymphoma (DLBCL) has become increasingly evident in recent years as not a single pathological entity. Wide-ranging diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to sub-categorize DLBCLs by their pathological characteristics and classify those associated with lower likelihood of cure with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) rituximab after typical first-line cure. This recognition has prompted expanded use of diagnostic testing to classify patients with high-risk severe lymphoma, the findings of which…
Zachary Frosch, MD of Penn Medicine @PennMedicine discusses stratification of molecular risk in aggressive b-cell lymphoma. Diffuse large B-cell lymphoma (DLBCL) has become increasingly evident in recent years as not a single pathological entity. Wide-ranging diagnostic techniques such as immunohistochemical staining and fluorescence in situ hybridization (FISH) have helped to sub-categorize DLBCLs by their pathological characteristics and classify those associated with lower likelihood of cure with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) rituximab after typical first-line cure. This recognition has prompted expanded use of diagnostic testing to classify patients with high-risk severe lymphoma, the findings of which have often led…
According to GlobalData, a leading data and analytics firm, India-based Curadev’s March 2020 licensing agreement with Bayer for the discovery and production of novel interferon gene stimulators (STING) antagonists across indications with high unmet need indicates the importance of the STING mechanism for research by top pharmaceutical companies. As part of the partnership, Bayer acquires exclusive access to the software of novel STING antagonists. The firms will jointly develop new drugs for lung cancer, cardiovascular disease and other inflammatory diseases. In 2019 Curadev approved Takeda’s STING agonist software (CRD5500). Under the deal, in addition to research funding, Curadev will receive…